Signals 02: December 2025

BCI Strategy Maturation & Therapeutic Neuromod Expansion

Signals is a market insights offering for commercial leaders covering key developments each month. It is available to paying members only.

December brought several major milestones across commercial neurotech sectors. Here’s what you’ll find in this edition of Signals:

• Neurable’s Series A tests investor appetite for consumer BCI

• Flow’s FDA approval puts at-home neuromodulation on the map

• NeuraWorx brings glymphatic modulation onto the map

• INSIGHTEC spins out Lotus Neuro, reframing FUS for life sciences

• Merge Labs emerges from nonprofit research

• Pathmaker’s FDA Breakthrough for multi-site DCS in ALS

• Neuralink is preparing for commercial readiness

• Science Corp’s Leadership Moves & Neurotech Chessboard